A Review on Psoriasis: Treatable but not Curable

Psoriasis is a chronic proliferative inflammatory skin disorder. Erythematous plaques with silvery scales are covered in Extensor surfaces, scalp, and lumbosacral area, The disease can also impair the eyes and joints. It is one of the most prevalent dermatological diseases and a continuous challenge in regards to therapeutic approach. The appearance of psoriasis is described by the Koebner Phenomenon. There are two types of psoriasis, Type 1 psoriasis has a positive family history, begins before the age of 40, and is linked to HLA-Cw6; Type 2 psoriasis has no family history, begins after the age of 40, and is not linked to HLA-Cw6. The Body Surface Area (BSA), Physician’s Global Assessment (PGA), Psoriasis Area and Severity Score (PASI), and Dermatology Life Quality Index are the most often used measures for assessing plaque psoriasis severity (DLQI), Psoriasis Area Severity Index (PASI) is the most extensively used assessment instrument for determining the severity of the illness and evaluating the treatment effectiveness. Topical treatment is employed for mild to moderate Psoriasis; biologics have a pragmatic strength of recommendation, which is often based on the patient’s case evidence and the drug’s performance. According to the American Academy of Dermatology and the National Psoriasis Foundation, biologic drugs are “engineered monoclonal antibodies and fusion proteins that exert their therapeutic activities by inhibiting cytokine receptors crucial to psoriatic inflammation”.